For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.
Biocon Biologics and Mylan said they have launched the long-acting insulin glargine product Semglee on the US market and hope to obtain formal biosimilar status for it. Semglee was approved in June as an equivalent to Sanofi’s Lantus insulin glargine, but not as a biosimilar, owing to the regulatory pathway taken.
It has been launched at a deep discount to the reference product and arrives at a time of great pushback against high insulin prices and limited competition. Many public and private health plans have been lowering out-of-pocket costs for patients to ensure access to this essential medicine.
Available in vials and prefilled pens, Semglee is for the control of high blood sugar in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. It is not recommended for patients with diabetic ketoacidosis.
Not a Full-Fledged Biosimilar
Although considered a biosimilar in other markets, Semglee doesn’t exactly qualify as such in the United States. It was approved via a new drug application under the Hatch-Waxman Act, a pathway traditionally used for generics and some biologics, including insulins. Because insulin approvals are now governed by the Biologics Price Competition and Innovation Act (BPCIA), and have been since March 2020, Semglee is now “deemed” a biologic.
“We are proud to be the first company, following the reference product, to receive FDA approval on and launch both the vial and pen presentations of an insulin glargine treatment with an identical amino acid sequence to Sanofi's Lantus,” said Mylan CEO Heather Bresch. She estimated the potential market for Semglee at 30 million Americans.
Mylan said it aims to have Semglee declared a full-fledged biosimilar to Lantus and has filed “all necessary documentation” to the FDA under the 351(k) pathway, which is the official BPCIA route for biosimilar approval. In addition, Mylan said it “remains confident in seeking an interchangeability designation” for the product as well.
Interchangeable designations allow pharmacists to fill prescriptions with biosimilars without consulting the prescribing physician. No current biosimilars have the interchangeable designation. It has been argued that there is such a high level of comfort with the safety and efficacy profile of insulins that approved products should be treated as interchangeable with originator products. Interchangeability would also speed the uptake of competing products.
Priced for Market Acceptance
To boost market acceptance of Semglee, Mylan, which serves as Biocon Biologics’ distribution partner in the United States, is offering packages of five 3-mL Semglee pens at the wholesale price of $147.98 and 10-mL individual vials at $98.65, which it called the lowest wholesale costs for any long-acting insulin glargine on the market.
“The list price of Semglee pen is equivalent to the Lantus launch price in 2007, and the Semglee vial is listed at Lantus’ 2010 pricing,” Mylan said in a statement. The individual vial cost of Lantus has climbed from $244 in 2013 to $431 in 2019, a 77% increase, according to a Senate Finance Committee letter.
Patient assistance programs or co-pay cards may further lower the cost, the statement said.
“We believe the US market represents a great opportunity for us and expect Semglee to contribute significantly to our goal of impacting 5 million patient lives and achieving $1 billion revenue by end of [fiscal year 2022],” said Christiane Hamacher, CEO of Biocon Biologics.
Semglee was approved based on analytical, preclinical, and clinical studies that confirmed the pharmacokinetics and pharmacodynamics, efficacy, safety, and immunogenicity of Semglee in comparison with Lantus in patients with type 1 and type 2 diabetes.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.